Zyversa Therapeutics, Inc. (ZVSA) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Zyversa Therapeutics, Inc. recently underwent a 1-for-35 reverse stock split on December 4, 2023, which poses a notable risk to shareholder value due to potential liquidity issues. The substantial reduction in outstanding shares may lead to decreased trading volume, making it more difficult for investors to buy and sell shares without impacting the market price. Furthermore, the increase in odd lot holdings could result in higher transaction costs and additional challenges for shareholders trying to liquidate their positions, potentially deterring investor interest and affecting the stock’s marketability.
The average ZVSA stock price target is $12.00, implying 1,400.00% upside potential.
To learn more about Zyversa Therapeutics, Inc.’s risk factors, click here.
